Journal of Medicine, Nursing & Public Health

Catatonia: Current Perspectives on Pathophysiology, Clinical Features, and Therapeutic Strategies

Farees Ahmad Khan, Muhammad Ismail Ahmad Khan Zalmay, Sarah Alnaher, Muhammad Zeshan

ISSN: 2706-6606

Stratford Peer Reviewed Journals and Book Publishing
Journal of Medicine, Nursing and Public Health
Volume 7||Issue 2 ||Page 79-91||September |2024|
Email: info@stratfordjournals.org ISSN: 2706-6606

Catatonia: Current Perspectives on Pathophysiology, Clinical Features, and Therapeutic Strategies

[1]*Farees Ahmad Khan, [2]Muhammad Ismail Ahmad Khan Zalmay, [3]Sarah Alnaher, [4]Muhammad Zeshan

*** Corresponding author's e-mail: ahmadfarees6@gmail.com**

***How to cite this article*: Khan, F. A., Khan Zalmay, M. I. A., Alnaher, S., & Zeshan, M. (2024). Catatonia: Current Perspectives On Pathophysiology, Clinical Features, And Therapeutic Strategies. *Journal of Medicine, Nursing and Public Health*, 7(2), 79-91. https://doi.org/10.53819/81018102t7027**

Abstract

Catatonia is a complex neuropsychiatric syndrome characterized by a spectrum of motor and behavioral symptoms, including stupor, catalepsy, and agitation. This review examines the current understanding of catatonia, focusing on its clinical presentation, pathophysiology, and treatment options. Catatonia can manifest in various forms, including motor abnormalities, altered mental status, and mood disturbances. Symptoms often include immobility, echolalia, and posturing, which may severely impact daily functioning and quality of life. The pathophysiology of catatonia involves disruptions in neural circuits, particularly in the supplementary motor area and prefrontal cortex. Key neurotransmitter systems, including GABAergic and glutamatergic pathways, are implicated. NMDA receptor dysfunction and autoimmune mechanisms are also significant areas of research. Prompt diagnosis and intervention are critical for favorable outcomes. Short-term treatment often includes benzodiazepines and electroconvulsive therapy (ECT), which can lead to rapid symptom resolution. Long-term outcomes vary based on the underlying condition and the duration of untreated catatonia. Untreated catatonia can lead to severe complications, including permanent neurological damage and progression to malignant catatonia. Advances in understanding catatonia are ongoing. Future research should focus on molecular and cellular mechanisms, genetic and epigenetic factors, and novel therapeutic interventions. Longitudinal studies are needed to assess the durability and safety of current treatments and to explore new approaches such as transcranial magnetic stimulation, deep brain stimulation, and emerging pharmacological agents. Further epidemiological studies are also necessary to determine the prevalence of catatonia across different populations and settings, considering cultural, environmental, and socioeconomic factors.

Keywords: *Catatonia, neuropsychiatric syndrome, benzodiazepines, NMDA receptor antagonists, multidisciplinary approach*

1.0 Introduction

Catatonia is a neuropsychiatric syndrome characterized by abnormal movements (such as stupor, akinesia, posturing, waxy flexibility, catalepsy, and stereotypies), behaviors (such as flat affect, fear, aggression, anxiety, impulsivity, and affect incontinence), and cognitive-behavioral abnormalities (such as mutism, grimacing, mannerisms, autism, negativism, automatic obedience,

echolalia, echopraxia, and rituals) [1-2]. Although catatonia can manifest in various medical, neurological, and psychotic disorders, it is most commonly associated with mood disorders.

The condition was first systematically described by Karl Ludwig Kahlbaum in 1874 [3]. Subsequently, Emil Kraepelin linked catatonia to one of the subtypes of dementia praecox, a term he used to describe early-onset schizophrenia. Eugen Bleuler further emphasized catatonia as a fundamental symptom of schizophrenia, highlighting its relationship with other psychotic disorders [3]. By the mid-20th century, the understanding of catatonia expanded to include its manifestations in mood disorders and various medical conditions.

The evolution of diagnostic criteria has played a significant role in the broader recognition of catatonia. Initially, the condition was closely associated with schizophrenia, as described in Kraepelin's and Bleuler's classifications. However, the introduction of the DSM-IV marked a pivotal shift by acknowledging catatonia's occurrence beyond schizophrenia, listing it as a specifier for mood disorders, psychotic disorders, and other medical conditions [3]. The DSM-5 further refined these criteria by recognizing catatonia as a syndrome that can occur independently of a specific underlying disorder [3]. This change emphasized the need for clinicians to consider catatonia as a potential diagnosis across a range of psychiatric and medical settings.

A meta-analysis involving 107,304 participants from 99 separate samples across all continents revealed that the total pooled mean prevalence of catatonia was 9.2% among individuals with a range of medical or psychiatric diagnoses [4]. This finding underscores that catatonia is a relatively common condition, affecting a significant portion of the population.

2.0 Methodology:

The literature search in this study was extensive, drawing on databases such as Google Scholar, PubMed, and Science Direct. The following search terms were used: "catatonia", "catatonia pathophysiology", "catatonia treatments", "catatonia diagnostic criteria", "clinical presentations". Inclusion criteria comprised peer-reviewed articles, research conducted in English, studies focusing on the clinical features, diagnostic criteria. etiology, pathophysiology, presentation in different with psychiatric conditions and treatments were included in this review. Exclusion criteria included non-peer-reviewed articles, grey literature, and papers in languages other than English. The selected studies were carefully reviewed, and data were extracted regarding study design and methodology, population and sample size, key findings related to the pathophysiology, clinical features, and therapeutic strategies of catatonia, as well as the limitations and strengths of each study. The extracted data were categorized and synthesized to provide a comprehensive framework for the current state of research into catatonia.

These findings were organized under themes such as historical perspectives, pathophysiology, diagnostic criteria evolution, clinical presentations, treatment modalities, and the prevalence of catatonia in various populations. To mitigate potential biases in study selection, a broad range of study designs was included, though the exclusion of non-English papers and grey literature may have limited the diversity of perspectives considered. Additionally, the varied sample sizes and methodologies of the included studies were acknowledged as factors that could influence the generalizability of the findings.

2.1 Clinical Presentation and Diagnostic Criteria

Under the DSM-5, catatonia is classified into three distinct types: catatonia associated with another mental disorder, catatonic disorder due to another medical condition, and unspecified catatonia [5].

2.1.1 Catatonia Associated with Another Mental Disorder (Catatonia Specifier):

For this diagnosis, only Criterion A needs to be met, which requires that the dominant clinical picture includes at least three of the following symptoms. Stupor is characterized by the absence of psychomotor activity and a lack of active engagement with the environment. Catalepsy involves the passive induction of a posture that is held against gravity, or rigidity and fixity of posture despite external stimuli. Waxy flexibility is identified by a slight, even resistance to positioning by an examiner, where a limb may be placed in an awkward position and remains fixed there, even when the individual is asked to relax. Mutism refers to little or no verbal response, excluding cases where aphasia is present. Negativism is exhibited as opposition or a lack of response to instructions or external stimuli.

Additional symptoms include posturing, where there is a spontaneous and active maintenance of a posture against gravity, and mannerism, which involves peculiar, circumstantial caricatures of normal actions. Stereotypy is characterized by repetitive, abnormally frequent, non-goal-directed movements. Agitation in this context is not influenced by external stimuli. Grimacing involves involuntary facial contortions, while echolalia and echopraxia are defined by mimicking another's speech and movements, respectively.

These core features are conveniently remembered using the mnemonic "WRENCHES": Waxy flexibility, Rigidity, Echopraxia, Negativism, Catalepsy, High level of motor activity, Echolalia, Stupor, and Stereotypy.

2.1.2 Catatonic Disorder Due to Another Medical Condition:

This diagnosis requires meeting all five of the following criteria (A-E). Criterion A involves the presence of at least three symptoms as previously outlined. Criterion B requires evidence from the patient's history, physical examination, or laboratory findings that the disturbance is a direct pathophysiological consequence of another medical condition, such as encephalitis or traumatic brain injury. Criterion C specifies that the disturbance cannot be better explained by another mental disorder, such as a manic episode. Criterion D ensures that the disturbance is not better explained by another medical disorder. Finally, Criterion E mandates that the disturbance does not occur exclusively during the course of a delirium. All these criteria must be met for a conclusive diagnosis.

2.1.3 Unspecified Catatonia:

This category applies to cases where symptoms characteristic of catatonia cause significant distress or impairment but do not meet the full criteria for any specific disorder within the Catatonia group. Catatonia can be further understood by categorizing its symptoms into three groups: decreased, increased, and abnormal psychomotor activity.

Decreased behaviors include stupor, negativism, mutism, posturing, and catalepsy. Abnormal behaviors are characterized by stereotypy, mannerism, waxy flexibility, echolalia, and echopraxia. Increased behaviors involve agitation and grimacing.

This detailed classification, as outlined in the DSM-5, highlights the heterogeneous nature of catatonia and its association with a variety of mental and medical conditions [5].

3. Etiology and Pathophysiology

3.1. Catatonia Pathophysiology Explanation by Neurotransmitter and Circuitry Dysfunction

Structural imaging findings in patients diagnosed with catatonia reveal non-homogeneous abnormalities, with the most commonly implicated cortical areas being the primary motor cortex, the supplementary motor area, the parietal cortex, and the ventromedial prefrontal cortex (vmPFC). Notably, the frontal and parietal cortices often show diminished volume, particularly in the right medial orbitofrontal cortex (OFC) and the superior left parietal gyrus. Additional findings include enlargement of the fronto-parietal cortical sulci, hypergyrification in the anterior cingulate gyrus, medial OFC, right inferior temporal gyrus, and right insula, and hypogyrification in the left superior temporal gyrus. Structural abnormalities such as atrophy of the cerebellar vermis and brainstem, as well as increased gray matter density in the cerebral cortex, have also been reported [6].

3.2. Role of the Supplementary Motor Area (SMA)

The SMA initiates, plans, learns, and programs motor behavior. It integrates successive elements into higher-order representations in complex cognitive processes such as music, language, and working memory. In lesions involving the SMA in non-catatonic patients, there are characteristic symptoms of slurred speech, perseverations, and repetitive movements. In catatonia, the typical symptom is the radical cessation of self-initiated movements and motor sequences.

Studies have further demonstrated that catatonic schizophrenic patients had increased cerebral blood flow to the SMA, which directly intensified according to the level of catatonia [6]. In addition, they reported a decreased gray matter amount of both the insular and frontal cortices of these patients. It is found that activation of the medial motor loop—that involves the SMA, the thalamus, and the basal ganglia—functioned within normal capacity in healthy controls during self-initiated movements, while this kind of activation was lacking in patients with catatonic schizophrenia [6]. The hyper direct pathway, projecting from the VIIb cerebellar region to the STN, on the other hand, is implicated in the inhibition of motor activity. This is through the suppression of M1 and SMA function through stimulation. The upregulated SMA hyper perfusion in catatonic patients could be indicative of a compensatory response to insufficient basal ganglionic output, apparently representing an effort to override intense motor suppression possibly due to cerebellar and the STN's activity.

3.3. Prefrontal Cortex Disruption

Functional neuroimaging showed marked disruptions in the OFC and vmPFC connections, in the ventromedial/dorsolateral PFC and premotor/motor cortex in the catatonic patients. There have been found reductions in cerebral blood flow in the right PFC and parietal cortex with respect to activity reduction of the GABA-A receptor in the left sensorimotor cortex and bilaterally in regard to activity reduction of the lower PFC. A "top-down" modulation model was proposed to explain akinesia and suggested that the dysregulation originates from the GABAergic and corticocortical

dysfunctions mediated by horizontal modulation within the OFC and PFC rather than from the motor loop itself [6].

The vmPFC-thalamic connections are important in cognitive and behavioral control. The vmPFC and dorsomedial prefrontal cortex (dmPFC) sends divergent projections to the mediodorsal thalamus and ventromedial striatum, respectively, that keep cognitive control tasks and direction of adaptive behavioral outputs. Hypofunction of the vmPFC and dmPFC, as demonstrated with catatonia, can hypothetically result in striatum activation that arrests behavior [6].

3.4. Dysfunction in Neurotransmitter Systems

The underlying mechanism of catatonia involves several important neurotransmitters that are both cellular and molecular in the pathophysiology, including glutamate, GABA, and dopamine. Akinetic catatonia is characterized by stupor, which could be explained by hypofunctioning GABAergic receptors resulting from intrinsic dysfunction or overriding due to excess glutamate or NMDA receptor activity. Such a notion of hypokinetic movements in catatonic patients responsive to lorazepam, a GABA-A agonist, is again supported by evidence [6].

Another major function that serotonin carries out in terms of modulating motor control is through this modulation of the VTA and the SN via the raphe nucleus, to decrease dopamine release into subcortical-cortical structures that are associated with motor control. This is critically involved in psychiatric conditions associated with catatonia, such as bipolar disorder and major depressive disorder, in which serotonin is fluctuated [6].

3.5. NMDA Receptor and Autoimmune Catatonia

Further evidence supporting the role of glutamatergic dysfunction in catatonia comes from studies on autoimmune catatonia, particularly in cases of NMDAR encephalitis. In NMDAR encephalitis, autoantibodies are primarily directed against the N1 subunit of the NMDA receptor, leading to receptor internalization. This internalization results in increased concentrations of extrasynaptic glutamate and disrupted synaptic signaling. Notably, NMDA receptor inhibitors, such as ketamine, have shown effectiveness in treating catatonia, likely due to their impact on the gene expression of calcium/calmodulin-dependent protein kinase II alpha (CaMK2A), which is involved in NMDA synaptic plasticity and long-term potentiation.

Recent evidence supports this therapeutic approach. Patients who did not fully respond to benzodiazepines (BDZ) showed improvement with the addition of NMDA inhibitors, including amantadine and memantine. For instance, patients with poor responses to BDZ treatment responded well when NMDA inhibitors like amantadine and memantine were introduced [6].

3.6. Dopaminergic Signaling

The dopaminergic system also contributes significantly to catatonia. Neuroleptic-induced catatonia related to first-generation antipsychotics is believed to be due to blockade of D2 receptors [6]. Some animal studies have shown that neuroleptics can produce a cataleptic state, which might be used as a model to describe the extrapyramidal symptoms of catatonia. The exact way in which the dysregulation of the dopaminergic mechanism leads to cataplexy is still not well understood, but the treatment responses to some extent paint valuable insights into the pathways involved in catatonia itself.

4. Catatonia in Specific Psychiatric Disorders

Catatonia is typically diagnosed in an inpatient setting and can occur in up to 10% - 25% of individuals with schizophrenia [7]. Estimating the prevalence of catatonia is challenging. Estimates suggest a prevalence ranging from 2-9% in consultation-liaison settings, 7-17% in inpatients with psychosis, and 15-31% in individuals with mood disorders [8].

4.1. Catatonia in Various Psychiatric Conditions:

A meta-analysis that included 74 studies with over 107,000 participants from diverse settings provided significant insights into the prevalence of catatonia across various psychiatric and medical conditions [4]. The analysis reveals that catatonia is notably more prevalent in bipolar disorder (BD) compared to schizophrenia and major depressive disorder (MDD). This finding aligns with previous literature suggesting that catatonia may be particularly common in mood disorders. In contrast, MDD was identified as a moderating factor that lowers the prevalence of catatonia, likely due to the use of second-generation antipsychotics (SGAs) at lower doses in MDD, which reduces the risk of extrapyramidal side effects associated with catatonia.

The prevalence of catatonia varies across different conditions. It is more common in individuals with medical conditions and decreases progressively in conditions such as schizophrenia, autism spectrum disorder (ASD), and mixed psychiatric illnesses [4].

4.2. Catatonia in Autism Spectrum Disorder (ASD):

Catatonia is estimated to affect about 10.4% of individuals with autism spectrum disorder (ASD), with a typical onset in late adolescence, peaking between ages 15 and 19 years. It predominantly affects males, with prevalence rates ranging from 70% to 100% [9]. Unlike the early developmental onset of ASD, catatonia in ASD represents a marked change in behavior with a distinct onset. Catatonia in ASD shares several symptoms with ASD, such as mutism, negativism, abnormal speech, posturing, and stereotypies, but these symptoms usually emerge as new or significantly worsened.

In ASD, catatonia often co-occurs with intellectual disability (ID), with co-occurrence rates ranging from 5.7% to 81.6% [9]. Clinical features of catatonia in ASD frequently include reduced speech, agitation, and self-harming behavior; obsessive-compulsive symptoms may sometimes precede the catatonic state.

Catatonia in ASD is often treatment-resistant. Although benzodiazepines, particularly lorazepam, are effective in many cases of catatonia, their response in individuals with ASD is generally poor [9]. Antipsychotics are also used but exhibit variable effectiveness and potential side effects. Understanding these unique clinical features and treatment responses is crucial for managing catatonia in individuals with ASD.

5. Differential Diagnosis

When evaluating a patient for catatonia, it is essential to consider several neurological and psychiatric conditions that can mimic catatonia, as some may even share similar underlying mechanisms [10]. Differentiating these conditions requires careful assessment, as their presentations can overlap, yet their management differs significantly.

A vegetative state, for example, is characterized by a complete lack of awareness due to severe brain injury, with preserved sleep-wake cycles but no voluntary responses to stimuli [11]. Unlike catatonia, where patients might exhibit normal EEG patterns, a vegetative state almost always presents with abnormal EEG findings, which aids in diagnosis [10]. Similarly, locked-in syndrome, typically caused by lesions in the ventral pons, results in near-total paralysis while sparing vertical eye movements and blinking [12]. Patients in this state are fully conscious and often attempt to communicate through eye movements, a key difference from catatonia. Diagnosis is confirmed through MRI or brainstem evoked potentials [10].

Another condition that can be challenging to distinguish from catatonia is nonconvulsive status epilepticus, which may present with immobility, mutism, and rigidity. However, an electroencephalogram (EEG) is crucial for an accurate diagnosis, as it can reveal ongoing seizure activity that differentiates this condition from catatonia [10].

Drug-induced parkinsonism is another important condition to consider, especially in psychiatric patients treated with antipsychotics. This condition presents with symptoms such as immobility, staring, and rigidity, which can be mistaken for catatonia [13]. However, unlike catatonic patients, those with parkinsonism tend to be more cooperative and engaged, and they often exhibit tremors, which are typically absent in catatonia. The key to differentiation lies in careful clinical assessment, as the treatments for these conditions are markedly different [10].

Neuroleptic malignant syndrome (NMS) also shares features with malignant catatonia, including rigidity, mutism, and autonomic instability. However, NMS is typically triggered by antipsychotic treatment and is characterized by additional symptoms such as delirium, sweating, hypertension, tachycardia, and fever. Immediate cessation of antipsychotics, along with supportive care, is crucial in managing NMS, and additional treatments like benzodiazepines or electroconvulsive therapy (ECT) may be necessary [14].

Stiff person syndrome, a rare autoimmune disorder, can present with stiffness and spasms that resemble catatonic posturing. However, patients with stiff person syndrome are usually not mute and can communicate their discomfort. The presence of GAD65 antibodies can help differentiate this condition from catatonia, with treatment typically involving benzodiazepines and immunotherapy [10].

Abulia or akinetic mutism are disorders characterized by a significant reduction in spontaneous speech or movement due to diminished motivation. While patients may be aware, they exhibit little drive to interact, and the absence of overt catatonic signs like negativism or echophenomena can help differentiate these conditions from catatonia. A trial of lorazepam may assist in making the diagnosis [10].

These conditions underscore the importance of a thorough differential diagnosis when assessing a patient for catatonia. Tools such as the Bush-Francis Catatonia Rating Scale can be instrumental in distinguishing catatonia from other conditions with overlapping symptoms, ensuring that patients receive appropriate and effective treatment [15].

Table 1 shows some of the conditions that could be confused with catatonia and some of the features that are similar to catatonia and some that some them different from catatonia [16].

Stratford Peer Reviewed Journals and Book Publishing
Journal of Medicine, Nursing and Public Health
Volume 7||Issue 2 ||Page 79-91||September |2024|
Email: info@stratfordjournals.org ISSN: 2706-6606

Table 1: Diagnosis Analysis

Diagnosis	Features Similar to Catatonia	Distinguishing Features
Non-catatonic stupor	Immobility, unresponsiveness, mutism, altered mental status	Clear precipitating cause (e.g., head trauma, anoxia, drug intoxication)
Encephalopathy	Acute onset, bizarre behavior, altered mental status	Typically occurs in the context of medical illness, reversible with treatment of underlying medical condition
Stroke	Acute onset, may present with immobility, mutism, and/or altered mental status	History of cerebrovacular disease, focal neurological signs, CT/MRI findings
Stiff-Person syndrome	Immobility, posturing	Stiffness and spasms precipitated by surprise
Parkinson's disease	Immobility, altered mental status, comorbid affective disorder	Symptoms improved with dopamine agonists and anticholingerics, cogwheel rigidity
Locked-in syndrome	Immobility, mutism	Complete paralysis with preserved vertical eye movements and blinking, associated with lesions in pons and cerebral peduncles
Malignant hyperthermia	Immobility, mutism, altered mental status, autonomic nervous system instability	Hyperthermia secondary to inhalation anesthetics, autosomal dominant, diagnosed with muscle biopsy
Status epilepticus	Immobility, mutism, altered mental status, bizarre behavior	Epileptiform activity in EEG
Autistic disorder	Mutism, immobility, echo-like behavior	Chronic with onset in childhood
Severe obsessive-compulsive disorder	Repetitive echo-like behavior, comorbid affective disorder	Anxiety, awareness of compulsive behavior
Elective mutism	Mutism	Possible underlying personality disorder or paranoia

6. Treatment and Management

6.1. Pharmacological Interventions: Benzodiazepines, ECT, Antipsychotics, NMDA Antagonists

6.1.1. Benzodiazepines

The first line of pharmacological intervention remains benzodiazepines, particularly intravenous or intramuscular lorazepam, considered the "gold standard" for both adult and pediatric catatonia. In a 14-year-old boy, who developed catatonia after receiving high doses of haloperidol, intravenous lorazepam demonstrated rapid efficacy with significant improvement within 40 minutes. This case therefore also illustrates that antipsychotic medications with prominent dopamine D2 receptor antagonism must be cautiously used because they can increase the risk of catatonia, especially in pediatric patients [17]. Similarly, in adults initially a 1-2 mg of Lorazepam is administered as both a diagnostic and therapeutic tool [18]. If the symptoms of catatonia improve, it confirms the diagnosis of catatonia. If the initial dose is not sufficient, the administration can be repeated every half to 1 h, and intravenous is favored for absorption and better compliance. When the patients do not respond completely to the intervention, rapid titration to 20 to 30 mg/day doses could be necessary to achieve full resolution of symptoms, with close monitoring for the beginning of sedation and respiratory depression [18].

Although lorazepam is the most frequently used benzodiazepine, other benzodiazepines such as diazepam, oxazepam, and clonazepam have also been reported to be effective. Zolpidem, a GABA-A receptor modulator, offers a safe and effective alternative for the treatment of catatonia, with 7.5 mg to 40 mg daily in a zolpidem challenge [18].

6.1.2. Electroconvulsive Therapy:

In those cases where benzodiazepines fail, the definitive treatment is electroconvulsive therapy. Excellent results of 80-100% response is seen with electroconvulsive therapy in most studies. It is especially recommended in cases of failure of benzodiazepines or when very fast resolution of the condition is required such as in conditions like neuroleptic malignant syndrome, malignant catatonia, and delirious catatonia [19]. One of the important drawbacks in administering ECT is that it requires a clear-cut consent which is very difficult to obtain in catatonic patients so ECT is considered a second-line treatment. Only after benzodiazepines have been tried and have failed to reduce the symptoms [20].

Treatment includes brief electrical brain stimulations under anesthesia which is thought to have an effect by increasing cerebral blood flow to the orbitofrontal and parietal cortices, resulting in increased GABA activity and GABA receptor expression [19]. In pediatric populations, ECT is generally a last option because some logistical and cultural difficulties exist in implementing it, even when safety and effectiveness have been proved [17].

Electroconvulsive therapy (ECT) is generally regarded as a safe procedure, even for patients with compromised medical conditions, as long as appropriate precautions are taken. Common side effects, such as cognitive impairment, headache, and muscle soreness, are usually mild and tend to resolve shortly after the treatment. In catatonic patients, serious complications from ECT are rare, particularly when the procedure is conducted in a controlled clinical environment with continuous monitoring.

Catatonic patients often present with physical health challenges that require careful management before ECT can be administered. In cases of malignant catatonia, which is characterized by hyperthermia and autonomic instability, it is crucial to initiate ECT within the first five days of hospitalization to improve response rates and reduce mortality. Bitemporal electrode placement is generally the most effective method for treating catatonia. To avoid sub-convulsive stimulation in patients with severe medical conditions, many practitioners use the half-age method to determine the appropriate stimulus intensity. A motor seizure lasting at least 25 seconds is desired, and if it is shorter, the stimulus intensity should be increased by 1.5 times in the following session [21].

ECT is typically administered three times a week on alternate days for catatonia, but in urgent cases, such as malignant catatonia, high-risk complications, delirious mania, or excited catatonia, daily treatments may be necessary until stabilization, which usually occurs within 2 to 5 treatments. After stabilization, the frequency of ECT can be reduced. The total number of sessions varies, with treatment effectiveness usually reviewed after 5 or 6 sessions and again after 10 or 12 sessions. ECT should be discontinued once complete clinical remission is achieved or if no further improvement is observed after two consecutive sessions. While most patients require between 12 to 20 treatments, some may achieve complete remission after just a few sessions [21].

During the course of ECT, psychotropic medications are generally withdrawn, although there is no uniform approach to the use of benzodiazepines. Some clinicians opt to withdraw benzodiazepines just before ECT, while others continue their use during and after treatment, theorizing that they may enhance the effects of ECT.

Traditionally, succinylcholine has been the muscle relaxant of choice for ECT due to its rapid onset and short duration. However, in catatonic patients, its use is often avoided because of the increased risk of severe hyperkalemia and susceptibility to neuroleptic malignant syndrome and malignant hyperthermia. As an alternative, rocuronium, with sugammadex for reversal, provides effective muscle relaxation with comparable onset and duration to succinylcholine, making it a viable option in these cases [21].

6.1.3. NMDA Antagonists

The NMDA antagonist amantadine has been reportedly effective for the treatment of catatonia. Intraparenchymal infusion of 500 mg amantadine has been reported to significantly improve catatonic symptoms in patients with acute akinetic catatonia within 4-6 hours; it can be repeated after 24 h [22]. However, the medication may exacerbate psychotic symptoms, thus studies are limited to patients with paranoid schizophrenia. Another trial reported that doses of up to 600 mg/day of amantadine, given for a period of up to four weeks, significantly reduced catatonic symptoms in patients with schizophrenia or schizoaffective disorder, with the greatest improvement noted between 10 and 21 days [22].

6.2. Non-Pharmacological Interventions and Supportive Care

Comprehensive management of catatonia also includes non-pharmacological approaches and aspects of supportive care. Maintenance of a safe environment, hydration, nutrition, and provision of psychological support to the patient and his or her family are essential components of care. Caregivers should be informed about the illness and the treatment course in order to have better compliance and lessened anxiety regarding use of treatments like ECT.

7. Prognosis and Outcomes

The prognosis of catatonia can vary significantly depending on timely diagnosis and intervention. Short-term outcomes are generally favorable when catatonia is promptly recognized and treated with appropriate therapies such as benzodiazepines or electroconvulsive therapy (ECT). Many patients experience rapid improvement, with symptoms often resolving within days to weeks of starting treatment.

Long-term outcomes, however, depend largely on the underlying condition and the duration of untreated catatonia. Patients with catatonia related to mood disorders, such as bipolar disorder, tend to have better long-term outcomes compared to those with catatonia associated with schizophrenia or other chronic psychiatric conditions. If catatonia is left untreated for an extended period, it can lead to serious complications, including permanent neurological damage, increased risk of mortality, or progression to malignant catatonia, which is a life-threatening condition.

Despite these insights, the long-term outcomes for patients with catatonia remain under-researched, particularly in resource-limited settings where access to timely diagnosis and treatment may be constrained. The variability in long-term outcomes underscores the need for more longitudinal studies to better understand the factors that influence prognosis. These studies should focus on the impact of early versus delayed treatment, the role of ongoing psychiatric care, and the potential for relapse or chronicity in different patient populations.

8.0 Future Research

The understanding of catatonia has evolved over the past century, and there remain several areas that require further exploration in order to improve clinical outcomes and the care of patients. Where research currently underlines the role of neurotransmitter systems and neural circuitry in catatonia, further exploration at a molecular and cellular level is required. One key avenue is the investigation of the genetic factors and epigenetic modifications that may contribute to the development of catatonia, which could unearth further novel therapeutic targets.

Longitudinal studies are well-designed for evaluation of long-term outcome of patients treated with the different modalities, especially benzodiazepines, ECT, and NMDA receptor antagonists. This would allow answering questions concerning the durability of treatment effects and the safety of these interventions in the long term. Given the complex pathophysiology, future studies of novel therapeutic interventions in catatonia are required; these could involve application of new neuromodulation techniques like transcranial magnetic stimulation or deep brain stimulation and emerging pharmacological agents acting at specific neurotransmitter systems or neural circuits implicated in catatonia.

Further epidemiological studies are hence required to clarify the exact prevalence of catatonia in various psychiatric and medical conditions. Such studies will have the potential to flesh out the global burden of catatonia, particularly in under-researched regions of the world and diverse populations, and may identify cultural, environmental, and socioeconomic factors that modulate the prevalence of and manifestation variables of catatonia.

9.0 Conclusion

The study concludes that catatonia, a neuropsychiatric syndrome with a highly heterogeneous etiology, clinical presentation, and treatment response, continues to pose significant diagnostic and therapeutic challenges. Despite advancements in understanding its pathophysiology, particularly

regarding neurotransmitter dysfunction and neural circuitry abnormalities, managing catatonia remains complex. Its occurrence across various psychiatric and medical conditions, such as mood disorders, schizophrenia, and neurodevelopmental disorders like ASD, highlights the necessity for a multidisciplinary approach. While the standard of care involving benzodiazepines and ECT is effective for many patients, a subset remains treatment-resistant. The potential of NMDA receptor antagonists and other emerging therapies offers hope for these cases, though further research is needed to optimize their application. Future research should focus on elucidating the underlying mechanisms of catatonia and conducting longitudinal studies to assess the long-term efficacy and safety of both current and novel treatments. Improving the recognition, diagnosis, and management of catatonia will require a concerted multidisciplinary effort in both clinical practice and research to enhance patient outcomes and quality of life.

References

1. Hirjak, D., Foucher, J. R., Ams, M., Jeanjean, L. C., Kubera, K. M., Wolf, R. C., & Northoff, G. (2024). The origins of catatonia – systematic review of historical texts between 1800 and 1900. *Schizophrenia Research, 263*, 6–17. https://doi.org/10.1016/j.schres.2022.06.003
2. Burrow JP, Spurling BC, Marwaha R. Catatonia. [Updated 2023 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430842/
3. Csihi, L., Ungvari, G. S., Caroff, S. N., & Gazdag, G. (2024). First 150 years of catatonia: Looking back at its complicated history and forward to the road ahead. *World Journal of Psychiatry*, *14*(5), 600–606. https://doi.org/10.5498/wjp.v14.i5.600
4. Solmi, M., Pigato, G. G., Roiter, B., Guaglianone, A., Martini, L., Fornaro, M., Monaco, F., Carvalho, A. F., Stubbs, B., Veronese, N., & Correll, C. U. (2018). Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis. *Schizophrenia bulletin*, *44*(5), 1133–1150. https://doi.org/10.1093/schbul/sbx157
5. *Catatonia*. PsychDB. (2023, November 23). https://www.psychdb.com/cl/0-catatonia#classification
6. Ariza-Salamanca DF, Corrales-Hernández MG, Pachón-Londoño MJ and Hernández-Duarte I (2022) Molecular and cellular mechanisms leading to catatonia: an integrative approach from clinical and preclinical evidence. Front. Mol. Neurosci. 15:993671. doi: 10.3389/fnmol.2022.993671
7. *Catatonic schizophrenia: What it is, symptoms & treatment*. Cleveland Clinic. (2022). https://my.clevelandclinic.org/health/diseases/23499-catatonic-schizophrenia
8. *Catatonia*. PsychDB. (2023a, November 23). https://www.psychdb.com/cl/0-catatonia#resources
9. Vaquerizo-Serrano, J., Salazar De Pablo, G., Singh, J., & Santosh, P. (2022). Catatonia in autism spectrum disorders: A systematic review and meta-analysis. *European Psychiatry*, *65*(1), e4. doi:10.1192/j.eurpsy.2021.2259
10. Rasmussen, S. A., Mazurek, M. F., & Rosebush, P. I. (2016). Catatonia: Our current understanding of its diagnosis, treatment and pathophysiology. *World journal of psychiatry*, *6*(4), 391–398. https://doi.org/10.5498/wjp.v6.i4.391

11. Quiñones-Ossa, G.A., Durango-Espinosa, Y.A., Janjua, T. *et al*. Persistent vegetative state: an overview. *Egypt J Neurosurg* **36**, 9 (2021). https://doi.org/10.1186/s41984-021-00111-3
12. Maiese, K. (2024, April). *Locked-in syndrome - locked-in syndrome*. Merck Manual Professional Edition. https://www.merckmanuals.com/professional/neurologic-disorders/coma-and-impaired-consciousness/locked-in-syndrome
13. Shiraiwa, N., Tamaoka, A., & Ohkoshi, N. (2018). Clinical features of drug-induced Parkinsonism. *Neurology international*, *10*(4), 7877. https://doi.org/10.4081/ni.2018.7877
14. Strawn, J. R., Keck, P. E., & Caroff, S. N. (2007). Neuroleptic malignant syndrome. *American Journal of Psychiatry*, *164*(6), 870–876. https://doi.org/10.1176/ajp.2007.164.6.870
15. *Bush-Francis Catatonia Rating Scale*. University of Rochester Medical Center. (n.d.). https://www.urmc.rochester.edu/psychiatry/divisions/collaborative-care-and-wellness/bush-francis-catatonia-rating-scale/bfcrs.aspx
16. Bhati, M. T., Datto, C. J., & O'Reardon, J. P. (2007). Clinical manifestations, diagnosis, and empirical treatments for catatonia. *Psychiatry (Edgmont (Pa. : Township))*, *4*(3), 46–52.
17. Sorg, E. M., Chaney-Catchpole, M., & Hazen, E. P. (2018). Pediatric catatonia: A case series-based review of presentation, evaluation, and Management. *Psychosomatics*, *59*(6), 531–538. https://doi.org/10.1016/j.psym.2018.05.012
18. Lloyd, J. R., Silverman, E. R., Kugler, J. L., & Cooper, J. J. (2020). Electroconvulsive Therapy for Patients with Catatonia: Current Perspectives. *Neuropsychiatric Disease and Treatment*, *16*, 2191–2208. https://doi.org/10.2147/NDT.S231573
19. Edinoff, A. N., Kaufman, S. E., Hollier, J. W., Virgen, C. G., Karam, C. A., Malone, G. W., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021). Catatonia: Clinical Overview of the Diagnosis, Treatment, and Clinical Challenges. *Neurology international*, *13*(4), 570–586. https://doi.org/10.3390/neurolint13040057
20. Rasmussen, S. A., Mazurek, M. F., & Rosebush, P. I. (2016). Catatonia: Our current understanding of its diagnosis, treatment and pathophysiology. *World journal of psychiatry*, *6*(4), 391–398. https://doi.org/10.5498/wjp.v6.i4.391
21. Luchini, F., Medda, P., Mariani, M. G., Mauri, M., Toni, C., & Perugi, G. (2015). Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response. *World journal of psychiatry*, *5*(2), 182–192. https://doi.org/10.5498/wjp.v5.i2.182
22. Pelzer, A. C., van der Heijden, F. M., & den Boer, E. (2018). Systematic review of catatonia treatment. *Neuropsychiatric Disease and Treatment*, *14*, 317–326. https://doi.org/10.2147/NDT.S147897